AUA Practice Guidelines Committee. AUA guidelines on management of benign prostatitis hyperplasia (2003). Chapter 1: Diagnosis and treatment recommendations. J Urol, 2003; 170(2 pt 1):530–547.
2.
LeporH, LoweFC. Benign prostatic hypertrophy: the molecular biology, endocrinology, and physiology of BPH. In: WalshPC, RetikAB, VaughnEDJr, WeinAJ, eds. Campbell's Urology. 8th ed. Philadelphia, PA: W.B. Saunders; 2002:1337–1377.
3.
RosenR, AltweinJ, BoyleP, et al.Lower urinary tract symptoms and male sexual dysfunction: the multinational survey of the aging male (MSAM-7). Eur Urol, 2003; 44:637–649.
RoehrbornCG, McConnellJD. Etiology, pathophysiology, epidemiology, and natural history of benign prostatic hyperplasia. In WalshPC, RetikAB, VaughnEDJr, WeinAJ, eds. Campbell's Urology. 8th edition. Philadelphia, PA: Saunders; 2002:1297–1336.
6.
NewmanDK. Managing and Treating Urinary Incontinence. Baltimore, MD: Health Professions Press; 2002.
7.
IssaMM, FenterTC, BlackL, GroggAL, KruepEJ. An assessment of the diagnosed prevalence of diseases in men 50 years of age or older. Am J Manag Care, 2006; 12(4 suppl):S83–S89.
8.
AbramsP, CardozoL, FallM, et al. The standardisation of terminology of lower urinary tract function: report from the Standardisation Subcommittee of the International Continence Society. Neurourol Urodyn, 2002; 21(2):167–178.
9.
RosenR. Multinational survey of the aging male (MSAM-7). Paper presented at: Annual Meeting of the American Urological Association; May 26, 2002; Orlando, FL.
RoehrbornCG, MarksL, HarkawayR. Enlarged prostate: a landmark national survey of its prevalence and impact on US men and their partners. Prostate Cancer Prostatic Dis, 2006; 9:30–34.
12.
LoganYT, BelgeriMT. Monotherapy versus combination drug therapy for the treatement of benign prostatic hyperplasia. Am J Geriatr Pharmacother, 2005; 3(2):103–114.
13.
McVaryKT. A review of combination therapy in patients with benign prostatic hyperplasia. Clin Ther, 2007; 29:387–398.
14.
Miano, De NunzioC, AsimakopoulousAD, GermaniS, TubaroA. Treatment options of benign prostatic hyperplasia in older men. Med Sci Monit, 2008; 14(7):RA94–RA102.
15.
AlschibajaM, MayF, TreiberU, PaulR, HartungR. Transurethral resection for benign prostatic hyperplasia. Current developments. Urologe A, 2005; 44:499–504.
16.
El-HakimAssaad. TURP in the new century: an analytical reappraisal in light of lasers. Can Urol Assoc J, 2010; 4:347–349.
17.
ReichO, BachmannA, SchneedeP, ZaakD, SulserT, HofstetterA. Experimental comparison of high power (80W) potassium titanyl phosphate laser vaporization and transurethral resection of the prostate. J Urol, 2004; 17(6 pt 1):2502–2504.
18.
BdeshaAS, BunceCJ, SnellME, WitherowRO. A sham controlled trial of transurethral microwave therapy with subsequent treatment of the control group. J Urol, 1994; 152(2 pt 1):453–458.
19.
D'AnconaFC, FranciscaEA, WitjesWP, WellingL, DebruyneFM, De la RosetteJJ. Transurethral resection of the prostate vs high-energy thermotherapy of the prostate in patients with benign prostatic hyperplasia: long-term results. Br J Urol, 1998; 81:259–264.
20.
De WildtMJ, D'AnconaFC, HubregsteM, CarterSS, DebruyneFM, de la RosetteJJ. Three-year followup of patients treated with lower energy microwave thermotherapy. J Urol, 1996; 156:1959–1963.
21.
KeijzersJM, FranciscaEA, D'AnconaFC, KiemeneyLA, DebruyneFM, de la RosetteJJ. Long-term results of lower energy transurethral microwave thermotherapy. J Urol, 1998; 159:1966–1973.
ZlottaAR, GiannakopoulosX, MaehlumO, OstremT, SchulmanCC. Long-term evaluation of transurethral needle ablation of the prostate (TUNA) for treatment of symptomatic benign prostatic hyperplasia: clinical outcome up to five years from three centers. Eur Urol, 2003; 44(1):89–93.
24.
FlaniganRC, RedaDJ, WassonJH, AndersonRJ, AbdellatifM, BruskewitzRC. 5-year outcomes of surgical resection and watchful waiting for men with moderately symptomatic benign prostatic hyperplasia: a Department of Veterans Affairs cooperative study. J Urol, 1998; 160(1):12–17.
25.
ChinPT, BoltonDM, JackG, et al.Prostatic urethral lift: two-year results after treatment for lower urinary symptoms secondary to benign prostatic hyperplasia. Urology, 2012; 79:5–11.
26.
Barkin J GiddensJ, InczeP, CaseyR, RichardsonS, GangeS. UroLift system for the relief of prostate obstruction under local anesthesia. Can J Urol, 2012; 19:6217–6222.
27.
WooHH, BoltonDM, LabordeE, et al.Preservation of sexual function with the prostatic urethral lift: a novel treatment for lower urinary tract symptoms secondary to benign prostatic hypertrophy. J Sex Med, 2012; 9:568–575.
28.
WooHH, ChinPT, McNicholasTA, et al.Safety and feasibility of the prostatic urethral lift: a novel minimally invasive treatment for lower urinary tract symptoms (LUTS) secondary to benign prostatic hyperplasia (BPH). BJU Int, 2011; 108(1):82–88.
29.
DelongchampsNB, ConquyS, DefontainesJ, ZerbibM, PeyromaureM. Pose d'implants UroLift intra-prostatiques pour hyperplasie benigne de la prostate: resultats preliminaires des quatre premiers cas realizes en France. Progres en Urologie, 2012; 22:590–597.
30.
RoehrbornCG, GangeSN, ShoreND, et al.Multi-center randomized controlled blinded study of the prostatic urethral lift for the treatment of LUTS associated with prostate enlargement due to BPH: the L.I.F.T. study. J Urol Epub ahead of print Jun10, 2013. pii: S0022-5347(13)04597-7. doi:10.1016/j.juro.2013.05.116.
31.
McNicholasTA, WooHH, ChinPT, et al: Minimally invasive prostatic urethral lift: surgical technique and multinational study. Eur Urol, 2013;(64):292–299.
32.
OelkeM, BachmannA, DescazeaudA, et al. Guidelines for the Treatment of Non-neurogenic Male LUTS. Arnhem (The Netherlands): European Association of Urology (EAU); March2011:70.
33.
McVaryKT, RoehrbornCG, AvinsAL, et al.Update on AUA guideline on the management of benign prostatic hyperplasia. J Urol, 2011; 185(5):1793–1803.
34.
StuckiP, MatteiA, MariniL, XafisK, DanuserH.Bipolar versus monopolar transurethral resection of the prostate: A prospective randomized trial focussin gon bleeding complications. Abstract 13-6339. Available at: http://www.aua2013.org/abstracts/archive/abstracts_MP73.cfm. Accessed September16, 2013.
35.
ElshalAM, ElmansyHM, ElhilaliMM. Two prostate laser ablation techniques: Lessons learned 70 months after a randomized controlled trial. Abstract 13-2000. Available at: http://www.aua2013.org/abstracts/archive/abstracts_MP73.cfm. Accessed September16, 2013.
36.
BergesR, SievertKD, GratzkeC, WetterauerU. UroLift®: an operative non-ablative procedure for treatment of benign prostatic syndrome. Urologe A, 2013; 52(3):350–353.
37.
Arenas da SilvaLF, SchonthalerM, CruzF, et al.Neue behandlungskonzepte von symptomen des unteren harntraktes beim mann. Urologue, 2012; 51:1697–1702.
38.
BellJ, LabordeE. Update on sexual impact of treatment for Benign Prostatic Hyperplasia. Curr Urol Rep, 2012; 13(6):433–440.
39.
BarryMJ, Edgman-LevitanS. Shared decision making – pinnacle of patient-centered care. N Engl J Med, 2012; 366:780–781.
40.
BraceC, SchmockerS, HuangH, VictorJC, McLeodRS, KennedyED. Physicians' awareness and attitudes toward decision aids for patients with cancer. J Clin Oncol, 2010; 28:2286–2292.
41.
ElwynG, FroshD, VolandesAE, EdwardsA, MontoriVM. Investing in deliberation: a definition and classification of decision support interventions for people facing difficult health decisions. Med Decis Making, 2010; 30(6):701–711.
42.
WiltTJ, BrawerMK, JonesKM, et al.Radical prostatectomy versus observation for localized prostate cancer. N Engl J Med, 2012; 367:203–213.
